Quest Diagnostics in the US has signed a multi-year agreement with Siemens Healthineers to procure up to 120 Atellica Solution immunoassay analysers.
With this procurement, Quest seeks to standardise its immunoassay testing across 19 esoteric and core laboratories in the country.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Designed to address common clinical laboratory challenges, Atellica Solution will help Quest Diagnostics in strengthening its immunoassay testing capacity and improving workflow efficiency.
Quest Diagnostics general diagnostics executive vice-president Jim Davis said: “Our strategic relationship with Siemens Healthineers led to the development of a flexible solution that will improve our existing workflow and help us achieve greater cost savings.
“We look forward to implementing this solution throughout our laboratory network.”
As part of the initiative, Atellica Solution immunoassay analysers will also be deployed in a highly automated Quest lab in Clifton, New Jersey.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAtellica will connect to an Inpeco FlexLab automation system to develop a high-throughput, multidisciplinary testing solution to optimise productivity and reduce operational costs.
Once the contract is fully realised, it will be the most extensive deployment of the Atellica Solution to date.
Siemens Healthineers Laboratory Diagnostics president Deepak Nath said: “Siemens Healthineers offers a comprehensive and quality in vitro diagnostics portfolio that is proving to be attractive to leading laboratory providers across the globe.
“Our leadership in workflow and automation is resonating with laboratories worldwide and driving adoption of the Atellica Solution.
“The breadth and depth of our testing solutions, a highly scalable and flexible offering with the Atellica Solution, and a broad immunoassay test menu with proven assay performance, will provide the clinical outcomes Quest Diagnostics requires.”
